CeQur is dedicated to helping people with diabetes by developing and commercializing simple drug delivery devices that can be easily integrated into daily life. The company has a platform of an extremely simple, discrete and wearable, 3-day device with the first generation being FDA cleared and CE marked. In July 2018, CeQur decided to focus its efforts to bring to market a unique and extremely simple 3-day bolus insulin delivery device, called CeQur Simplicity. This device allows a person to administer insulin in a simple, discreet way by just clicking the two buttons. It is extremely slim and is virtually undetectable under clothing. Bolusing can be done over clothing, so there is no reason to step away from friends to discreetly deliver a dose. (www.myceqursimplicity.com). CeQur Simplicity is designed to revolutionize insulin delivery by providing a convenient, discreet and inject free solution to insulin delivery that is easy to teach and prescribe. The word “revolutionize” is key. In a world full of complex devices - Simplicity makes it extremely easy to take insulin and ensure compliance to therapy. The 3-day bolus device is FDA cleared for adults requiring insulin and is currently in a pilot launch stage in 2021. We are working with select physicians and centers to bring this innovative technology to patients. The CeQur Simplicity device will be available broadly soon. CeQur Simplicity device has been tested in three clinical studies that demonstrated the device is effective, safe and easy to use. Moreover the studies highlighted that it has high patient satisfaction over daily injections and strong participant desire to stay on the wearable bolus device versus going back to injections. CeQur is headquartered in Horw, Switzerland, with operations in Marlborough, Massachusetts.